Patent · US Active

Soluble immunoreactive treponema pallidum TpN47 antigens

US9316642B2 · kind B2 · utility

0Cited by

0References

15Claims

0Family size

Assignee

Roche Diagnostics Operations, Inc. · US

Inventors

Elke Faatz · Huglfing, DE
Peter Schaarschmidt · Ulm, DE
Urban Schmitt · Oberhausen, DE
Christian Scholz · Penzberg, DE

Key dates

Filing date	Jul 18, 2014
Grant date	Apr 19, 2016
Priority date	—
Expiry date	Jul 18, 2034

Classification

Technology area (CPC G)Physics
CPC primaryG01N2469/20
WIPO fieldMeasurement
WIPO sectorInstruments

Abstract

The invention concerns soluble variants of Treponema pallidum antigen 47 (TpN47 antigen) comprising at least domain B, or at least domains A and B, optionally domain D of the complete TpN47 protein molecule with the proviso that all antigens lack domain C (amino acid residues 224 to 351) of TpN47. The Tpn47 antigens can be fused to a chaperone. Moreover, the invention covers DNA encoding the antigens, a method of producing these antigens as well as the use of these antigens in an immunodiagnostic assay for the detection of antibodies against Treponema pallidum in an isolated sample.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.